Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Reporter's Eye: 5
April 18, 2005
- MEDICAL DEVICE NEWS IN BRIEF
April 18, 2005
- NEW PRODUCTS
April 18, 2005
- Tanabe Seiyaku Working to Strengthen Quality Assurance System
April 18, 2005
- Nu-lotan Shows High Evidence Scores in Clinical Studies
April 18, 2005
- The Reporter's Eye: 3
April 11, 2005
- MPC Adds SP Codes to All Its Ethical Drugs
April 11, 2005
- Astellas Sets Out with 2,500 MRs in Japan
April 11, 2005
- OTC/HEALTH FOOD NEWS IN BRIEF
April 11, 2005
- Eisai Carries Out Organizational Restructuring
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Toho to Tie Up with 6 Regional Wholesalers
April 11, 2005
- Average Foreign Price Adjustment Rule Comes Under Criticism Again
April 11, 2005
- IMS to Boost Consulting Business to 20% of Sales
April 11, 2005
- Schering-Plough KK Aims for Sales of \100 Bil. by FY2010
April 11, 2005
- BUSINESS NEWS IN BRIEF
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Roche's Anticancer Agent Tarceva Approved in Switzerland
April 11, 2005
- Amended PAL Goes into Full Effect
April 11, 2005
- Self-injection to Be Allowed for INF a, Etanercept
April 11, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…